NCT06868485 - A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

WSD0922-FU Tablets, Dose level A

Oral, 21 days in each cycle

DRUG

WSD0922-FU Tablets, Dose level B

Oral, 21 days in each cycle

Trial Locations (18)

14000

RECRUITING

Centre Francois Baclesse, Caen

15235

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

33331

RECRUITING

Cleveland Clinic Weston Hospital, Weston

33604

RECRUITING

CHU Bordeaux - Centre Francois Magendie, Pessac

35000

RECRUITING

Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou, Rennes

44195

RECRUITING

Cleveland Clinic, Cleveland

48201

RECRUITING

Karmanos Cancer Institute, Detroit

78745

RECRUITING

TxO Central/South, Texas Oncology -Central/South Texas, Austin

83100

RECRUITING

CHU Toulon - Hopital Sainte Musse, Toulon

87042

RECRUITING

Centre Hospitalier Universitaire CHU De Limoges, Limoges

93030

RECRUITING

FOMAT Oncology, Oxnard

200120

RECRUITING

Shanghai East hospital, Shanghai

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

300202

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

350014

RECRUITING

Fujian Provincial Cancer Hospital, Fuzhou

430022

RECRUITING

Wuhan Union Hospital, Wuhan

08050

RECRUITING

Hackensack Meridian Health-Southern Ocean Medical Center, Manahawkin

All Listed Sponsors

lead

Wayshine Biopharm, Inc.

INDUSTRY